Understanding the evolution of neuroblastoma to improve treatment
Single-cell transcriptomics linked to lineage tracing to interrogate the role of intra-tumour heterogeneity in shaping therapeutic susceptibility and resistance in paediatric cancer
Developing innovative new treatments for difficult to treat types of medulloblastoma
Developing and delivering small molecule drug and immunotherapy combinations for MYC-driven medulloblastoma: Efficacy, evolution and exploitation.
Improving treatment decisions and outcomes in low grade glioma
Development of a multi-factorial prognostic model to optimise treatment decision making and outcomes in paediatric low-grade glioma
Using next-generation gene technology to help children with blood cancers in low-income countries.
Defining the molecular landscape of paediatric and adolescent acute leukaemia in Tanzania
How does neuroblastoma begin and can we use this knowledge to develop new treatments?
Dissecting the role of MYCN in neuroblastoma initiation
Optimising therapy in newly diagnosed metastatic Ewing sarcoma
Optimising tyrosine kinase inhibitor therapy in newly diagnosed metastatic Ewing sarcoma
Evaluating the use of novel treatments in combination with current maintenance therapies for the on-going treatment of high-risk neuroblastomas
Evaluating the efficacy of Enhancer of Zeste Homolog 2 (EZH2) inhibitors in combination with anti-GD2/isotretinoin for the treatment of high-risk neuroblastoma: a pre-clinical study
Towards chemotherapy-free treatment of lymphoid tumours in children with solid organ transplants
Towards chemotherapy-free treatment of paediatric post-transplant lymphoproliferative disorders
Living with treatment-related hearing loss: Experiences of survivors of childhood brain cancer
Living with treatment-related hearing loss: Experiences of survivors of childhood brain cancer